### COPD Pharmacotherapy Position Statement

**COPD Working Group - CONFLICT OF INTEREST**

<table>
<thead>
<tr>
<th>Name</th>
<th>CTS affiliation</th>
<th>Disclosure</th>
<th>Updated</th>
</tr>
</thead>
</table>
| Aaron, Shawn    | COPD            | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
**Academic appointment(s)/employment:** Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Chief, Division of Respiratory Medicine, The Ottawa Hospital, Professor, Division of Respirology, University of Ottawa  
**University:** University of Ottawa  
**Hospital:** The Ottawa Hospital  
**Research Funding:**  
**Peer-reviewed grants:** CIHR  
**Consultant/Advisor:**  
**Industry advisory board member:** Glaxo Smith Kline, Astra Zeneca, Novartis, and Boehringer-Ingelheim  
**Honoraria:**  
**Speaker:** $1500 for Astra Zeneca  
**Volunteer/Board or Committee Member:**  
**Charitable Organization/Not for profit:** The Ontario Lung Association | May 2017 |
| Balter, Meyer   | COPD            | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
**Academic appointment(s)/employment:** Professor of Medicine  
**University:** University of Toronto  
**Hospital:** Mount Sinai Hospital  
**Consultant/Advisor:**  
**Industry advisory board member:** AstraZeneca, Boehringer-Ingelheim, Novartis, TEVA  
**Honoraria:**  
**Speaker:** AstraZeneca, Boehringer-Ingelheim, Novartis  
**CME/Course development:**  
**Development of educational material:** AstraZeneca, Boehringer-Ingelheim  
**Volunteer/Board or Committee Member:**  
**Charitable Organization/Not for profit:** ACCP | March 2017 |
<table>
<thead>
<tr>
<th>Name</th>
<th>CTS affiliation</th>
<th>Disclosure</th>
<th>Updated</th>
</tr>
</thead>
</table>
| Beauchesne, Marie-France | External expert approved by the CTS Board of Directors | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).  
**Academic appointment(s)/employment:**  
**University:** Faculté de pharmacie, Université de Montréal  
**Hospital:** Département de pharmacie, CIUSSS de l’Estrie-CHUS  
**Other:** Centre de recherché du CHUS  
**Research Funding:**  
Other: Research projects initiated by the investigator and sponsored by the pharmaceutical industry (note: all protocols have been peer reviewed by the scientific and ethics committee of the CR CHUS). | March 2017 |

<table>
<thead>
<tr>
<th>Projet Title</th>
<th>Source of Funding</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Validité externe des essais cliniques randomisés contrôlés sur les médicaments inhalés en maladie pulmonaire obstructive chronique et évaluation des préférences et techniques d’inhalation des médicaments inhalés des patients (Étude VERITAS)</td>
<td>AstraZeneca</td>
<td>34 212,50 $</td>
</tr>
<tr>
<td>Support for the CIUSSS de l’Estrie-CHUS “RESP” database</td>
<td>AstraZeneca</td>
<td>15 000$</td>
</tr>
<tr>
<td>Caractérisation des patients asthmatiques non-contrôlés, ayant une MPOC ou le syndrome de chevauchement de l’asthme et de la MPOC</td>
<td>Boehringer-Ingelheim</td>
<td>11 290$</td>
</tr>
<tr>
<td>Projet d’amélioration de la pratique et suivi systématique d’une clientèle vulnérable MPOC</td>
<td>Novartis</td>
<td>10 000$</td>
</tr>
<tr>
<td>Long-acting anticholinergics (LAAC) in patients with chronic obstructive pulmonary disease (COPD): adherence, persistence, and side effects.</td>
<td>Almirall (AstraZeneca)</td>
<td>93 870,25 $</td>
</tr>
<tr>
<td>Name</td>
<td>CTS affiliation</td>
<td>Disclosure</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Beauchesne (con’td) |               | **Honoraria:**
|               |                | **Speaker:** I have received honoraria from the pharmaceutical industry for the following CME in the last year:
|               |                | 2016, Mai 3 - Gestion de la MPOC en Établissement de santé au Québec. Webconférence subventionnée par Bl.
|               |                | 2016, Mai 26 - Projet d’amélioration de la pratique auprès des patients MPOC vulnérables. Webconférence subventionnée par Novartis.
|               |                | 2016, Mai 31 - Caractérisation des patients asthmatiques, MPOC et ACOS. Webconférence subventionnée par Bl.
|               |                | 2016, Décembre 6 - Usage des médicaments pour MPOC en CHSLD, WebConférence pour les hôpitaux de la province, subventionnée par Novartis.
|               |                | **CME/Course development:**
|               |                | Peer Reviewer: Review of the CME program titled “Changing the conversation. Adding the art of medicine to asthma management” sponsored by AstraZeneca.
<p>|               |                | <strong>Other (please specify):</strong> Co-holder of the endowment AstraZeneca pharmaceutical Chair.                                                                                                              |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>CTS affiliation</th>
<th>Disclosure</th>
</tr>
</thead>
</table>
| Bhutani, Mohit | COPD            | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
**Academic appointment/employment:**  
University: University of Alberta  
Hospital: University Hospital  
Research Funding: CIHR, AIHS  
**Peer-reviewed grants:** CIHR, AFHS  
**Industry-sponsored contracts:** AZ, BI, GSK, Novartis  
**Consultant/Advisor:**  
**Industry advisory board member:** AZ, BI, GSK, Novartis  
**Honoraria:**  
**Speaker:** AZ, BI, GSK, Novartis  
**CME/Course development:** AZ, BI, GSK, Novartis |
Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).

**Academic appointment(s)/employment:**
- **University:** Full professor at McGill University
- **Hospital:** Respirologist, Montreal Chest Institute of the Royal Victoria Hospital, of the McGill University Health Centre

**Other:**
- Director, Centre of Innovative Medicine, The Research Institute of the McGill University Health Centre
- Director, COPD clinic and pulmonary rehabilitation, McGill University Health Centre
- Member of Scientific Committee Global Initiative for COPD (GOLD)
- Member, Pulmonary Rehab Assembly, American Thoracic Society
- Pneumologue expert du Comité du Réseau montréalais en maladies chroniques
- Member of the COPD committee Canadian Thoracic Society

**Research Funding:**

**Peer-reviewed grants:**

**CIHR**
- 2017/4 - 2020/3 - Principal Applicant - COPD disease categorization using cardiovascular risk and levels of inflammatory mediators: a way to toward more personalized care
- 2015/3 - 2020/2 - Co-investigator - Development and validation of Canadian health literacy measurement tool for chronic disease management
- 2015/2 - 2019/12 - Principal Applicant - Better understanding of chronic obstructive pulmonary disease (COPD) and intervention
- 2014/3 - 2019/2 - Co-investigator - Optimizing physician training in motivational communication (MC) skills for health behavior change
- 2016/3 - 2019/2 - Co-investigator - Developing Longitudinal Indicators for Population-Scale Monitoring of Health Care Trajectories

**CRRN**
- 2014/4 - 2018/3 - Principal Applicant - Canadian Cohort Obstructive Lung Disease (CanCOLD)

**Industry**

**GlaxoSmithKline** –
- 2015/2 - 2019/12 - Principal Applicant - Better understanding of chronic obstructive pulmonary disease (COPD) and intervention
- 2016/12 - 2017/11 - Principal Applicant - Understanding symptoms (dyspnea) in COPD from mild to moderate-severe disease

**Grifols** –
- 2016/12 - 2019/11 - Principal Applicant - A1ATD: Genetic sequencing and COPD characterization in a population-based COPD Cohort

### Updated
- October 2017
<table>
<thead>
<tr>
<th>Name</th>
<th>CTS affiliation</th>
<th>Disclosure</th>
</tr>
</thead>
</table>
| Bourbeau (cont’d)  |                                                                                 | **Aerocrine** -  
  • 2015/7 - 2018/6 - Principal Applicant - FeNO in COPD  
**Consultant/Advisor:**  
Industry advisory board member:  
• Boehringer Ingelheim (National and International)  
• AstraZeneca (National)  
• Novartis (National)  
• GlaxoSmithKline (International)  
**Government Agency:**  
CIHR: Reviewer  
Other government body or committee: Provincial Ministry of Health: Chronic respiratory disease committee on the Montreal Territory  
**Honoraria:**  
Speaker: McGill University Health Centre, University de Montréal (UDM), Canadian Thoracic Society, CHEST, Many worldwide respiratory societies, Pharma Industry, (Boehringer Ingelheim, Grifols, AstraZeneca, Novartis)  
**CME/Course development:** PREP CTS CHEST  
Development of educational material: Respiplus (Living Well With COPD), Resptrec, RQESR  
**Volunteer/Board or Committee Member:** CTS, Respiplus, Réseau en santé respiratoire du FRQS, RQESR, RESPTrec  
**Charitable Organization/Not for profit:** Quebec Lung Association, Fondation Québécoise en santé respiratoire  
As a member of the CTS Board of Directors are you:  
Related to a provincial or federal government employee or official (please specify): No |
| D’Urzo, Anthony     | Appointed by the Canadian Family Physicians of Canada                           | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
**Academic appointment(s)/employment:**  
University: University of Toronto, Faculty of medicine, Dept of family and Community Medicine.  
Hospital: Toronto Western Hospital  
**Research Funding:**  
**Industry-sponsored contracts:** Novartis Canada/AstraZeneca Canada/Boehringer Ingelheim (Canada)  
**Consultant/Advisor:** Novartis Canada/Global AstraZeneca Canada/Boehringer Ingelheim (Canada)  
**Industry advisory board member:** TEVA Pharmaceuticals Canada, Novartis Canada/Global AstraZeneca Canada/Boehringer Ingelheim (Canada)  
**Honoraria:** Merck Canada, Novartis Canada/Global AstraZeneca Canada/Boehringer Ingelheim (Canada), TEVA Pharmaceuticals Canada  
**Speaker:** Merck Canada, Novartis Canada/Global AstraZeneca Canada/Boehringer Ingelheim (Canada)  
**CME/Course development:** Development of educational material: Novartis Canada |

COPD Pharmacotherapy Position Statement - CONFLICT OF INTEREST- 2017
<table>
<thead>
<tr>
<th>Name</th>
<th>CTS affiliation</th>
<th>Disclosure</th>
<th>Updated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goldstein, Roger</td>
<td>COPD</td>
<td>Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</td>
<td>April 2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Academic appointment(s)/employment:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>University: Toronto</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital: West Park</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consultant/Advisor:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Provincial Ministry of Health: Yes</td>
<td></td>
</tr>
<tr>
<td>Hernandez, Paul</td>
<td>COPD CRGC</td>
<td>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</td>
<td>March 2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Academic appointment(s)/employment:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>University: Dalhousie University</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital: QEII Health Sciences Centre, Nova Scotia Health Authority</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Research Funding:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peer-reviewed grants: CIHR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Industry-sponsored contracts:</strong> Boehringer Ingelheim; Prometic; Grifols; CSL Behring</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consultant/Advisor:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Industry advisory board member:</strong> Actelion; AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Grifols; Merck; Novartis; Roche</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Honoraria:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speaker: AstraZeneca; Bayer; Boehringer Ingelheim; Grifols; Merck; Novartis; Roche</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CME/Course development:</strong> Boehringer Ingelheim; CTS; MD Briefcase; Development of educational material:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peer Reviewer: Dalhousie University Academic Detailing Service</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Volunteer/Board or Committee Member:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Charitable Organization/Not for profit:</strong> Lung Association of Nova Scotia</td>
<td></td>
</tr>
<tr>
<td>Kaplan, Alan</td>
<td>COPD Pediatric Assembly</td>
<td>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).</td>
<td>March 2017</td>
</tr>
<tr>
<td></td>
<td>Appointed by the Canadian Family Physicians of Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Academic appointment(s)/employment:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>University: Toronto</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consultant/Advisor:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Industry advisory board member:</strong> Boehringer, Astra, GSK, Meda, Pfizer, Novartis, Purdue, Teva</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Government Agency:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Health Canada: Section of Allergy and Respiratory Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Public Health Agency of Canada: Respiratory Surveillance</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Honoraria:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speaker: Boehringer, Astra, GSK, Merck, Pfizer, Purdue, NovartisJohnson and Johnson,</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>CTS affiliation</td>
<td>Disclosure</td>
<td>Updated</td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
</tbody>
</table>
| Maltais, François  | COPD HMV                                  | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).  
**Academic appointment(s)/employment:**  
**University:** Professor, Université Laval  
**Hospital:** Institut Universitaire de cardiologie et de pneumologie de Québec  
**Research Funding:**  
**Peer-reviewed grants:** CIHR, CRRN  
**Industry-sponsored contracts:** Novartis, Griffols, Boehringer Ingelheim, AstraZeneca  
**Consultant/Advisor:**  
**Industry advisory board member:** Novartis  
**Government Agencies:**  
**Drug approval committee:** INESSS (ad hoc committee in 2015)  
**Honoraria:**  
**Speaker:** Boehringer Ingelheim, Novartis, Griffols  
**Volunteer/Board or Committee Member:**  
**Charitable Organization/Not for profit:** FRQS (scientific review committee) |         |
| Marciniuk, Darcy   | COPD CTS Long-Term Planning Committee     | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest (s).  
**Academic appointment/employment:**  
**University:** Saskatchewan  
**Hospital:** Royal University Hospital  
**Research Funding:**  
**Peer-reviewed grants:** CIHR, Canada Health Infoway, Lung Assoc of Saskatchewan Health Research Foundation  
**Industry-sponsored contracts:** AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Schering-Plough  
**Other:** Lung Health Institute  
**Consultant/Advisor:**  
**Government Agency:** Canadian Foundation for Healthcare Improvement, Health Canada, Lung Association of Saskatchewan, Chinese Committee of Health and Family Planning  
**Provincial Ministry of Health:** Saskatchewan  
**Other government body or committee:** Saskatoon Health Region, Regina-Qu’Appelle Health Region  
**International NGO:** ATS, CHEST, FIRS  
**Volunteer/Board or Committee Member:** Lung Health Institute of Canada | April 2017 |
<table>
<thead>
<tr>
<th>Name</th>
<th>CTS affiliation</th>
<th>Disclosure</th>
<th>Updated</th>
</tr>
</thead>
</table>
| O’Donnell, Denis| COPD            | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
**Academic appointment(s)/employment:** Member, Division of Respirology  
**Professor (Medicine, Biomedical & Molecular Sciences, Kinesiology & Health Studies)**  
**University:** Queen’s University  
**Hospital:** Kingston General Hospital  
**Research Funding:**  
**Peer-reviewed grants:**  
  - William Spear & Richard Start Funds, Queen’s University  
  - Ontario Thoracic Society Grant-in-Aid  
  - Canadian Respiratory Research Network  
  - CIHR Research & Development Research Program  
  - Department of Medicine Research Award, Queen’s University  
  - SEAMO Clinician Scientist Development Program  
**Industry-sponsored contracts:** Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline  
**Consultant/Advisor:**  
  - Industry advisory board member: Almirall, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer  
**Honoraria:**  
  - Speaker: Almirall, Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer | March 2017 |
| Sin, Don        | COPD            | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has led to a real or perceived conflict of interest(s).  
**Academic appointment(s)/employment:**  
**University:** University of British Columbia  
**Hospital:** St. Paul’s Hospital  
**Research Funding:**  
**Peer-reviewed grants:** CIHR, Genome Canada  
**Industry-sponsored contracts:** Merck, AstraZeneca, BI  
**Consultant/Advisor:**  
**Industry advisory board member:** Regneron, Sanofi, BI, Vitaeris, Naegis Pharmaceuticals, AstraZeneca, Novartis  
**Honoraria:**  
**Speaker:** AstraZeneca, BI  
**CME/Course development:** St. Paul’s Hospital Continuing Medical Education, UBC Respiratory Update  
**Volunteer/Board or Committee Member:**  
**Charitable Organization/Not for profit:** CIHR |